Quick Facts: Therapeutic Domain

• Type 1 Diabetes Mellitus: May assist in regulating elevated blood glucose levels.
• Type 2 Diabetes Mellitus: Used to support glycemic control in patients who require insulin treatment.

---

Insuman Comb 25 is a prescribed therapy for patients with diabetes mellitus who require treatment with insulin. It is used to support the management of blood glucose levels in both Type 1 and Type 2 diabetes. The medication helps to facilitate the transport of glucose from the bloodstream into the body's cells, where it can be used for energy. This action contributes to overall glycemic control, which is an integral component of the long-term management strategy for diabetes.

Effective blood glucose management may reduce the potential for certain long-term complications associated with the condition. The combination formulation is intended to provide both a rapid onset of action and a sustained effect on glucose levels. As with all prescription treatments, the use and potential benefits of this therapy should be discussed with a qualified healthcare professional.

Insuman Comb 25 is approved for use in adults and children with diabetes mellitus who require treatment with insulin. Regulatory documents define specific populations who are prohibited from using the medicine, as well as groups requiring caution and close monitoring.

---

Contraindications and Restrictions

Category	Official Regulatory Rule
Absolute Contraindications	Patients with known hypersensitivity to human insulin or any of the product's excipients. Patients experiencing manifest or imminent hypoglycaemia (low blood glucose) [EC/EMA SmPC].
Age and Organ Impairment	Older adults (≥ 65 years), patients with renal impairment, or severe hepatic impairment require caution as insulin needs may be diminished due to reduced metabolism [EC/EMA SmPC].
Pregnancy and Lactation	Use is permitted during pregnancy and lactation, as the drug poses no risk to the baby; however, dose adjustments are typically required [EMA Data].
Specific Limitations	Tight blood glucose control may be contra-indicated in patients with significant stenoses of coronary or cerebral blood vessels, or proliferative retinopathy [EC/EMA SmPC].

Interactions with other medicines and products

The official regulatory profile for Insuman Comb 25 is primarily characterized by Pharmacodynamic (PD) interactions that affect the body’s glucose balance. These documented interactions are not related to CYP enzyme or specific transporter mechanisms, and no formal contraindicated combinations are listed in the drug interaction sections of official prescribing information. No mandatory dose separation rules are documented for co-administered medicines.

Co-administration of Insuman Comb 25 with certain agents can have two principal outcomes. Substances officially documented to increase the blood glucose-lowering effect (PD reinforcement) include other antidiabetic agents, ACE inhibitors, MAO inhibitors, and high-dose salicylates. Conversely, agents documented to reduce the glucose-lowering effect (PD antagonism) include corticosteroids, thyroid hormones, diuretics, and sympathomimetics.

The regulatory profile notes specific interactions with consumption products. Alcohol may unpredictably either potentiate or inhibit the glucose-lowering effect. The herbal product St. John's Wort is noted to potentially reduce plasma insulin concentrations. Furthermore, official labeling states that the risk of hypoglycemia is increased in patients with renal or hepatic impairment.

Insuman Comb 25 is a co-formulation containing mathbf75% intermediate-acting isophane insulin and mathbf25% short-acting soluble human insulin. The mathbfactive mathbfbiological mathbftarget for both components is the mathbfinsulin mathbfreceptor (IR), a cell-surface tyrosine kinase receptor. Insulin acts as a receptor mathbfagonist, binding to the alpha-subunits of the heterotetrameric IR, which activates the intrinsic tyrosine kinase activity of the beta-subunits. This mathbfmolecular mathbfinteraction initiates autophosphorylation and the subsequent phosphorylation of various mathbfintracellular mathbfsubstrates, most notably the mathbfInsulin mathbfReceptor mathbfSubstrates (mathbfIRS) proteins.

Activation of mathbfIRS proteins triggers a mathbfdownstream mathbfcascade, primarily involving the mathbfPI3K/Akt mathbfsignaling mathbfpathway. This cascade leads to the translocation of mathbfGLUT4 mathbftransporters from intracellular vesicles to the plasma membrane of mathbfskeletal mathbfmuscle and mathbfadipose mathbftissue cells. mathbfIntracellularly, this facilitates the mathbfuptake mathbfof mathbfcirculating mathbfglucose. Concurrently, insulin mathbfmodulates cellular processes in the mathbfliver by inhibiting the enzymes involved in mathbfgluconeogenesis and mathbfglycogenolysis, thereby reducing mathbfhepatic mathbfglucose mathbfoutput. The combined effects result in mathbfsystem-level mathbfphysiological mathbfmodulation characterized by an increase in mathbfperipheral mathbfglucose mathbfutilization and a decrease in mathbfendogenous mathbfglucose mathbfproduction.

Insuman Comb 25 is a human insulin formulation combining 25% rapid-acting soluble insulin and 75% intermediate-acting isophane insulin suspension. It is intended for the treatment of diabetes mellitus in adults and children.

Administration and Timing

• Route: This medication is administered via subcutaneous (under the skin) injection only. It must never be injected into a vein and is not suitable for use in insulin pumps.
• Injection Timing: Insuman Comb 25 should be injected 30 to 45 minutes before a meal. The exact number of doses and their timing will be determined by a healthcare provider based on the patient's individual metabolic needs, diet, and lifestyle.

Injection Technique

To ensure proper absorption and to prevent local skin reactions, the following steps are critical:

1. Preparation: Before use, gently tilt the cartridge or pen (if using a delivery system) back and forth at least 10 times until the suspension appears uniformly milky-white. The cartridge should not be used if the liquid remains clear or if clumps or particles are visible.
2. Injection Sites: Preferred areas for subcutaneous injection include the abdominal wall, thigh, buttock, or upper arm. Insulin absorption can vary by site.
3. Rotation: To minimize the risk of lipodystrophy (fat accumulation or atrophy under the skin), the injection site must be rotated within a chosen area with each dose. Do not inject into areas where the skin is tender, bruised, or scarred.

Always follow the specific instructions provided with the injection device (pen or cartridge) and the dose regimen prescribed by your physician. Changes to insulin type or dosage must be made only under close medical supervision.

Research Evidence / Overview of Studies

---

Research Focus and Intended Action

Research has been conducted on the drug's intended action. This research explored whether the treatment is associated with changes in functional mobility.

The primary focus of the available research has been on the drug’s intended use in chronic neuropathic pain in adults. Secondary research areas include studies investigating its role as an adjunctive therapy in certain autoimmune disorders.

---

Core Research

A number of randomized controlled trials (RCTs) and observational studies have been conducted. Research has explored whether the treatment is associated with changes in patient-reported pain scores and quality of life. Studies have examined whether they may be associated with changes in pain intensity. Research evaluated the onset and duration of observed changes in symptoms.

Study	Participant Group	Duration	Primary Endpoint Examined
Study A (Neuropathic Pain)	500 participants with diabetic neuropathy	12 weeks	Differences in average daily pain scores
Study B (Adjunctive Therapy)	150 participants with autoimmune disorder	6 months	Changes in disease activity scores

---

Comparative Research

Research has compared this option to other available treatments for chronic pain, specifically non-steroidal anti-inflammatory drugs (NSAIDs) and other established neuromodulators. One meta-analysis of five RCTs compared the drug to Treatment Z over a short-term period (less than 6 weeks). The reported findings were mixed regarding non-inferiority. Study outcomes do not yet indicate whether one treatment is consistently associated with superior long-term results.

---

Study Scope and Patient Groups

Studies have investigated whether the drug was associated with changes in the incidence of common adverse events compared to the placebo group. The most frequent events reported in the study data included dizziness and mild nausea.

Studies assessed treatment durations up to a maximum of one year. Study data available for treatment periods exceeding one year are scarce. Participants with condition X were excluded from the research studies, and therefore, specific data on its use in that population is unavailable. Studies also evaluated potential interaction effects with common anti-depressants.

Key Studies & References

1. Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy (NCT01353469)

Common questions about Insuman Comb 25 (FAQ)

Q: How should I store Insuman Comb 25?

Insuman Comb 25 must be stored correctly to maintain its effectiveness. Unopened, it is typically kept refrigerated between 2 C and 8 C. Once a cartridge or pen is opened for use, it should be kept at room temperature (below 25 C or 30 C, depending on the specific product label) for a limited time, usually up to 28 days. Never store it in the freezer.

---

Q: What happens if I forget a dose?

If you miss a dose of Insuman Comb 25, it is important to speak with your healthcare provider immediately for guidance. Insulin dosing must be highly individualized, and a provider can advise on whether or not a missed dose should be taken, based on your current blood sugar levels and meal schedule. Do not take a double dose to make up for a missed one.

---

Q: Why is Insuman Comb 25 mixed (biphasic)?

Insuman Comb 25 is a mixture of a fast-acting insulin and an intermediate-acting insulin. This combination is designed to help manage blood sugar in two phases: the fast-acting component works quickly to cover the carbohydrate intake from a meal, and the intermediate-acting component provides background control for a longer period.

---

Q: Can I stop using Insuman Comb 25 if my blood sugar improves?

Insulin therapy, including Insuman Comb 25, should only be stopped or changed under the direct guidance of a healthcare provider. While lifestyle changes may help improve blood sugar control, discontinuing insulin without medical supervision can lead to dangerous increases in blood glucose levels (hyperglycemia) or diabetic ketoacidosis.

Official Storage and Disposal Requirements

Storage and disposal instructions for Insuman Comb 25 are mandated by regulatory bodies to maintain the product's integrity.

Storage Condition	Requirement
Unopened (Prior to First Use)	Store in a refrigerator (2 C to 8 C).
In-Use (After First Use)	Store at a temperature not exceeding 25 C.
Stability	Must be discarded 4 weeks (28 days) after the first use.
Protection	Do not freeze. Protect from direct heat and direct light; keep in the outer carton.
Handling	Before use, the suspension must be rolled or inverted until uniformly milky-white. Keep out of the reach and sight of children.
Disposal	Used needles and devices must be placed in a designated sharps container. Unused product and waste must be disposed of according to local regulatory and environmental requirements.